The MIDD just recently started to collaborate with , a new startup company that is located at the new 51ÁÔÆæ chemistry building. CEO and cofounder Gunnar Gottschalk and CSO and co-founder Avik Roy are focusing on the development of a novel drug candidates for triple negative breast cancer. The MIDD will support Simmpyra during preclinical studies. Recently, Simmpyra Pharmaceuticals submitted a SBIR grant to accelerate their efforts in drug development.